Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review

Ding,Qun‑Li; Lv,Dan; Wang,Bi‑Jiong; Zhang,Qiao‑Li; Yu,Yi‑Ming; Sun,Shi‑Fang; Chen,Zhong‑Bo; Ma,Hong‑Ying; Deng,Zai‑Chun

doi:10.3892/etm.2015.2183

Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review

Authors:
- Qun‑Li Ding
- Dan Lv
- Bi‑Jiong Wang
- Qiao‑Li Zhang
- Yi‑Ming Yu
- Shi‑Fang Sun
- Zhong‑Bo Chen
- Hong‑Ying Ma
- Zai‑Chun Deng
View Affiliations

Affiliations: Department of Respiratory Medicine, Affiliated Hospital, School of Medicine, Ningbo University, Ningbo, Zhejiang 315020, P.R. China
Published online on: January 15, 2015 https://doi.org/10.3892/etm.2015.2183
Pages: 829-834

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cryptogenic organizing pneumonia (COP) is a pulmonary disorder associated with nonspecific clinical presentations. The macrolide class of antimicrobial agents is widely used to treat infectious and inflammatory respiratory diseases in humans. The present study reports a case of COP that was effectively treated with azithromycin in combination with glucocorticoid. A literature review of similar cases is also presented. It was found that all COP patients in the literature received macrolide treatment, including six cases with unknown clinical outcomes. For the remaining 29 patients, 20 patients initially received the macrolide as a single therapy and 4/5 of them (16 cases) were cured with a treatment time of 3‑14 months, while 1/5 (4 cases) showed no improvement after treatment for 1 month and were switched to a glucocorticoid or combination treatment with a glucocorticoid, after which the disease was finally well‑controlled. Side‑effects of macrolide were rare. Based on this analysis, it is recommended that macrolides can be used as a first‑line therapy in patients with mild COP. For patients with recurrent COP, it is suggested that macrolides should be used as an adjunctive therapy with other treatments, such as a glucocorticoid.

View Figures

View References

1	Drakopanagiotakis F, Paschalaki K, et al: Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic findings, treatment response and prognosis. Chest. 139:893–900. 2011. View Article : Google Scholar
2	American Thoracic Society and European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 165:277–304. 2002.
3	Drakopanagiotakis F, Polychronopoulos V and Judson MA: Organizing pneumonia. Am J Med Sci. 335:34–39. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hatipoglu U and Rubinstein I: Low-dose, long-term macrolide therapy in asthma: An overview. Clin Mol Allergy. 2:42004. View Article : Google Scholar : PubMed/NCBI
5	Chang WJ, Lee EJ, Lee SY, In KH, Kim CH, Kim HK and Park S: Successful salvage treatment of steroid-refractory bronchiolar COP with low-dose macrolide. Pathol Int. 62:144–148. 2012. View Article : Google Scholar : PubMed/NCBI
6	Radzikowska E, Wiatr E, Gawryluk D, et al: Organizing pneumonia - clarithromycin treatment. Pneumonol Alergol Pol. 76:334–339. 2008.(In Polish).
7	Vaz AP, Morais A, Melo N, et al: Azithromycin as an adjuvant therapy in cryptogenic organizing pneumonia. Rev Port Pneumol. 17:186–189. 2011.(In Portuguese). View Article : Google Scholar : PubMed/NCBI
8	Lee J, Cha SI, Park TI, Park JY, Jung TH and Kim CH: Adjunctive effects of cyclosporine and macrolide in rapidly progressive cryptogenic organizing pneumonia with no prompt response to steroid. Intern Med. 50:475–479. 2011. View Article : Google Scholar : PubMed/NCBI
9	Mukae H, Kadota J, Kohno S, Matsukura S and Hara K: Increase of activated T-cells in BAL fluid of Japanese patients with bronchiolitis obliterans organizing pneumonia and chronic eosinophilic pneumonia. Chest. 108:123–128. 1995. View Article : Google Scholar : PubMed/NCBI
10	Cai M, Bonella F, Dai H, Sarria R, Guzman J and Costabel U: Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. Immunobiology. 218:930–937. 2013. View Article : Google Scholar
11	Yousem SA, Lohr RH and Colby TV: Idiopathic bronchiolitis obliterans organizing pneumonia/cryptogenic organizing pneumonia with unfavorable outcome: pathologic predictors. Mod Pathol. 10:864–871. 1997.PubMed/NCBI
12	Ichikawa Y, Ninomiya H, Katsuki M, Hotta M, Tanaka M and Oizumi K: Low-dose/long-term erythromycin for treatment of bronchiolitis obliterans organizing pneumonia (BOOP). Kurume Med J. 40:65–67. 1993. View Article : Google Scholar : PubMed/NCBI
13	Ishii T, Manabe A, Ebihara Y, Ueda T, Yoshino H, Mitsui T, et al: Improvement in bronchiolitis obliterans organizing pneumonia in a child after allogeneic bone marrow transplantation by a combination of oral prednisolone and low dose erythromycin. Bone Marrow Transplant. 26:907–910. 2000. View Article : Google Scholar : PubMed/NCBI
14	Stover DE and Mangino D: Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia? Chest. 128:3611–3617. 2005. View Article : Google Scholar : PubMed/NCBI
15	Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombolà L, Carnuccio R, et al: Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 292:156–163. 2000.
16	Luisi F, Gandolfi TD, Daudt AD, Sanvitto JP, Pitrez PM and Pinto LA: Anti-inflammatory effects of macrolides in childhood lung diseases. J Bras Pneumol. 38:786–796. 2012. View Article : Google Scholar
17	Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E and Zarogoulidis K: Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol. 68:479–503. 2012. View Article : Google Scholar
18	Wagner T and Burns JL: Anti-inflammatory properties of macrolides. Pediatr Infect Dis J. 26:75–76. 2007. View Article : Google Scholar : PubMed/NCBI
19	Langelot M, Cellerin L and Germaud P: Anti-inflammatory effects of macrolides: applications in lung disease. Rev Pneumol Clin. 62:215–222. 2006.(In French). View Article : Google Scholar : PubMed/NCBI
20	Davidson R and Peloquin P: Anti-inflammatory effects of the macrolides. J Otolaryngol. 31(Suppl 1): 38–40. 2002. View Article : Google Scholar
21	Kudoh S: Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med. 4:116–121. 1998. View Article : Google Scholar : PubMed/NCBI
22	Itkin IH and Menzel ML: The use of macrolide antibiotic substances in the treatment of asthma. J Allergy. 45:146–162. 1970. View Article : Google Scholar : PubMed/NCBI
23	Sharma S, Jaffe A and Dixon G: Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis. Paediatr Drugs. 9:107–118. 2007. View Article : Google Scholar : PubMed/NCBI